# Lupin receives USFDA approval for Cephalexin Capsules

| BSE: 500257 | NSE: LUPIN | REUTERS: LUPN.BO | BLOOMBERG: LPC IN |
|---|---|---|---|

*Mumbai, December 1, 2005:* Lupin Ltd announced that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Cephalexin Capsules USP 250 mg and 500 mg. The US market for Cephalexin Capsules is estimated at USD 80 million.

This is Lupin's eighth ANDA approval by the USFDA till date and the third in this financial year. Earlier this year, the Company had received approvals from the US FDA for Lisinopril tablets and Cephalexin for Oral Suspension. The approval makes Lupin one of the select few integrated players who offer both Cephalexin capsules and suspension in the US market.

A main stay cephalosporin antibiotic, Cephalexin is indicated for the treatment of Respiratory tract infections caused by S. pneumoniae and S. pyogenes, skin and skin structure infections caused by staphylococci and/or streptococci, bone infections caused by staphylococci and/or P. mirabilis and genitourinary tract infections, including acute prostatitis, caused by E. coli, P. mirabilis, and K. pneumoniae.

**About Lupin**

Headquartered in Mumbai, Lupin (http:/www.lupinworld.com) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion. 11 of Lupin's plant have been approved by the USFDA and two facilities have been approved by the UKMHRA

For further information contact:
**Raju Kane**
**The Source**
**Mobile: +91 98200 45656**
E-mail: **mail@sourcepr.com**